No CrossRef data available.
Article contents
Open-label: the clinical effects of adding cannbidiol to usual care of patients with residual symptoms in the diagnosis of Obsessive Compulsive Disorder
Published online by Cambridge University Press: 19 July 2023
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
Obsessive-compulsive disorder (OCD) is a heterogeneous and debilitating neuropsychiatric disorder. First-line antidepressants with Selective Serotonin Reuptake Inhibitors (SSRIs) and Clomipramine (a tricyclic antidepressant) are unresponsive or partially responsive in 40% of treated patients. Preclinical studies have shown that cannabidiol (CBD) can reduce compulsive behavior in animals, and considering that the release of glutamate in the action of CBD can inhibit terminal axons of neurons in the corticostriatal-thalamo-cortical circuit, we chosefor testing CBD, a drug with few side effects and low toxicity, as an adjuvant in treating OCD.
Objectives
To evaluate the clinical effects of CBD add-on to the usual pharmacological treatment of outpatients diagnosed with OCD.
Methods
Methods: This is an open-label study in which patients received CBD 300mg-day for 30 days in addition to their usual treatments and CBD 600mg-day for an additional 30 days if they have not reduced at least 25% of symptoms compared to the baseline evaluated by the Yale-brown obsessive-compulsive scale (Y-BOCS). Psychometric scales were used to assess the effects of CBD: Y-BOCS, General Anxiety Disorder 7 (GAD-7), Clinical Overall Impressions-Severity (CGI-S), Clinical Global Impressions-Improvement (CGI-I), Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale and Udvalg Scale for Kliniske Undersogelser (UKU) scale.
Participants: We initially assessed 33 participants in the study. So far, 19 patients have completed the study. Eleven did not complete the study, and 03 patients are still in the study trial.
Results
a
Mean (SD) Y-BOCS scores decreased from 28.0 (4.8) at baseline to 13.8 (8.6) at week 8, corresponding to a - 50.7% reduction (P<.0001). Anxiety symptoms (GAD-7 scale) (P=0.001) and CGI-Severity scales scores (P<0.001) improved significantly.
| Measure | Baseline, Mean (SD) | Week 4, Mean (SD) | Week 8, Mean (SD) | Mean Change (Baseline to Week 4) | Mean Change (Baseline to Week 8) | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean (SD) | p-value | t-test | |||||||
| Y-Bocks | 28.0 (4.8) | 17.8 (7.3) | 13.8 (8.6) | 10.1 (6.5) | <0,001 | 7.1 | 14.1 (7.9) | <0,001 | 7.7 |
| GAD-7 | 13.8 (4.4) | 8.14 (4.9) | 8.0 (5.7) | 5.7 (6.4) | 0,001 | 4.0 | 5.6 (5.8) | 0,001 | 4.1 |
| CGI-I | 5.48 (0.9) | 3.9 (1.3) | 3.3 (1.5) | 1.5 (1.3) | <0,001 | 5.28 | 2.1 (1.2) | <0,001 | 7.4 |
n=22;
bn=19
Image:
Image 2:
Image 3:
Conclusions
We concluded that there was an important reduction in the psychometric scales used with statistical significance. This is a partial analysis of the results as the study progresses. We believe that in the future we will be able to complete this study and have a better analysis of the results that are promising. At the end of the study, other psychometric scales such as CGI-I, epworth scale and UKU will be analyzed.
Disclosure of Interest
None Declared
- Type
- Abstract
- Information
- European Psychiatry , Volume 66 , Special Issue S1: Abstracts of the 31st European Congress of Psychiatry , March 2023 , pp. S225 - S226
- Creative Commons
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.- Copyright
- © The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
You have
Access
Open access
Comments
No Comments have been published for this article.